Japan's Sawai considers future hunt for partner; U.S. regulators warn CSL on flu-vax plant

 @FiercePharma: Novartis faces new obstacle in Alcon deal. Article | Follow @FiercePharma

> Drugmakers shopping for a Japanese partner, take note: Sawai Pharmaceutical, Japan's No.1 generics maker, says it will need to consider a capital tie-up with a bigger drugmaker in the future. Report

> U.S. health regulators have cautioned Australia's CSL after uncovering problems at its influenza vaccine manufacturing plant and want to meet with company officials. Report

> Israeli drugmaker Teva Pharmaceutical says it won FDA approval for a generic version of Wyeth's antidepressant drug Effexor XR. Report

> AstraZeneca Pharma India said it has received a delisting offer from 90 percent-owner AstraZeneca Pharmaceuticals AB, sending its shares higher. Report

> Teva Pharmaceutical Industries won the green light from FDA to sell its generic version of AstraZeneca's cancer blockbuster Arimidex. Report

> Indian drugmaker Dr. Reddy's Laboratories said it has launched a copycat version of AstraZeneca's breast cancer drug Arimidex in the U.S. Report

> Perrigo acquired exclusive U.S. store brand rights for over-the-counter versions of the Sanofi-Aventis allergy drugs Allegra and Allegra D-12. Release

Biotech News

@FierceBiotech: Pharma pipelines mired by poor productivity, shrinking R&D budgets. Article | Follow @FierceBiotech

@JohnCFierce: IBM says that cloud computing can help reduce the 8-12% of trial costs related to data juggling. Article | @JohnCFierce

> Sanofi plans 'industrial scale' PhIII program for dengue vaccine. Item

> Forest pain drug fails to beat out a placebo in PhII. Report

> Bind banks $12.4M round as lead program heads into PhI. News

Biotech Research News

> Harvard, Yale researchers make strides in lung regeneration. Article

> French adopt new approach to biomedical research. Item

> NIH research budget to shrivel as Obama demands discipline. Report

> Developers lobby for new federal R&D incentives for rare diseases. News

> ViaCyte wins kudos for ESC program to treat diabetes. Story

> Nanotubes used to detect proteins. Article

Pharma Manufacturing News

> J&J expects plant fixes to take all year. News

> Dendreon scrambles to boost Provenge production. Report

> New markets for pharma bring supply-chain worries. Item

> ViroPharma aims to double manufacturing capacity. Story

> Contract manufacturing to see double-digit growth. News

And Finally... Could public transit be the answer to the obesity epidemic? Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.